| 1.74 -0.11 (-5.95%) | 02-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.53 | 1-year : | 2.87 |
| Resists | First : | 2.16 | Second : | 2.46 |
| Pivot price | 1.96 |
|||
| Supports | First : | 1.7 | Second : | 1.41 |
| MAs | MA(5) : | 1.86 |
MA(20) : | 1.94 |
| MA(100) : | 2.62 |
MA(250) : | 2.79 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 16.2 |
D(3) : | 22.6 |
| RSI | RSI(14): 41.5 |
|||
| 52-week | High : | 4.5 | Low : | 1.61 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AIMD ] has closed above bottom band by 20.4%. Bollinger Bands are 8.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.89 - 1.91 | 1.91 - 1.92 |
| Low: | 1.69 - 1.72 | 1.72 - 1.73 |
| Close: | 1.71 - 1.75 | 1.75 - 1.77 |
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
Mon, 09 Feb 2026
Chip plants get AI 'nose' as Ainos turns factory smells into data - Stock Titan
Wed, 04 Feb 2026
Inside the AI Nose winning $2.1M orders to teach machines to smell - Stock Titan
Fri, 30 Jan 2026
Taiwan carbon nano tech sells Ainos (AIMD) shares for $99,806 By Investing.com - Investing.com Nigeria
Thu, 29 Jan 2026
Insider Sell: Taiwan Carbon Nano Technology Corp Sells 46,000 Sh - GuruFocus
Wed, 28 Jan 2026
Ainos Expands SmellTech Strategy with Trusval Agreement - StocksToTrade
Wed, 28 Jan 2026
12 Information Technology Stocks Moving In Wednesday's Intraday Session - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 2.92e+006 (%) |
| Held by Institutions | 61.7 (%) |
| Shares Short | 23 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.56e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -128 % |
| Return on Assets (ttm) | 481.4 % |
| Return on Equity (ttm) | -33.2 % |
| Qtrly Rev. Growth | 113040 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -43.33 |
| EBITDA (p.s.) | 37995.9 |
| Qtrly Earnings Growth | -4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 2.03 |
| Dividend | 0 |
| Forward Dividend | 17670 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|